Lonza is investing approximately CHF 500 million to construct a large-scale commercial drug product fill and finish facility in Stein (CH). The investment will enable the company to provide customers with an integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply. The new facility is expected to be completed in 2026.
 
Pierre-Alain Ruffieux, CEO, Lonza, said, “This strategic investment completes our offering in drug product and strengthens our position as a leading CDMO with an unparalleled breadth of offerings across scales and technologies. Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an integrated end-to-end offering across their entire product life cycle.”
 
Since establishing drug product development and manufacturing services in 2016, Lonza has expanded its clinical drug product offering in Basel, Stein and Visp (CH), and Guangzhou (CN). This significant new investment in commercial drug product manufacturing completes Lonza’s strategic commitment to offer an integrated end-to-end service.
 
The new flexible facility will be constructed in Stein on the same campus as Lonza’s current clinical drug product facility, allowing the company to leverage the existing infrastructure, capabilities and talent.